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Background: Although myelodysplastic syndromes are heterogeneous disorders 
comprising a benign subset of bone marrow failure similar to aplastic anemia, no 
laboratory test has been established to distinguish it from bone marrow failures that can 
evolve into acute myeloid leukemia.   
Design and Methods: Plasma thrombopoietin levels were measured in 120 patients 
who had myelodysplastic syndrome with thrombocytopenia (< 100 x 109/L) to 
determine any correlation to markers associated with immune pathophysiology and 
outcome.   
Results: Thrombopoietin levels were consistently low for patients with refractory 
anemia with excess of blasts, while patients with other myelodysplatic syndrome 
subsets had more variable results.  Patients with thrombopoietin levels ≥320 pg/mL 
had increased glycosylphosphatidylinositol-anchored protein-deficient blood cells 
(49.1% versus 0%), were more likely to have a low International Prognostic Scoring 
System (IPSS) score (≤1.0, 100% versus 65.5%), a higher response rate to 
immunosuppressive therapy (84.2% versus 14.3%), and a better 5-years 
progression-free survival rate (94.1% versus 63.6% for refractory cytopenia with 
unilineage dysplasia; 100.0% versus 44.4% for refractory cytopenia with multilineage 
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dysplasia).   
Conclusions: Increased plasma thrombopoietin levels were associated with a favorable 
prognosis of bone marrow failure and could therefore represent a reliable marker for a 
benign subset of myelodysplastic syndrome. 
 




Myelodysplastic syndromes (MDS) are characterized by peripheral cytopenia and 
morphological abnormalities in mature and immature blood cells.  Although MDS 
were originally defined as clonal hematopoietic disorders with a propensity to become 
acute myeloid leukemia (AML), they also comprise benign bone marrow (BM) failure 
which may benefit from immunosuppressive therapy (IST) like acquired aplastic anemia 
(AA) does.(1-3)  MDS with thrombocytopenia are often difficult to differentiate from 
non-severe AA because diagnoses rely on a subjective judgment of blood cell 
morphological abnormalities, and BM cellularity is often inconsistent among the sites 
examined.(4, 5)  Laboratory markers such as glycosylphosphatidylinositol-anchored 
protein-deficient (GPI-AP-) cells and HLA-DRB1*1501 may differentiate between 
benign and preleukemic MDS subtypes.(6, 7)  Diagnostic values of these markers have 
not been established, however, due to conflicting results in the prediction of IST 
response (8) and cumbersome procedures in the detection of minor GPI-AP- cell 
populations.(9, 10)  
Thrombocytopenia is a symptom common to AA and a subset of MDS.  
Previous studies showed that plasma levels of thrombopoietin (TPO), a critical regulator 
of thrombopoiesis, were elevated in patients with AA (11) but remained low in patients 
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with MDS despite the presence of severe thrombocytopenia.(12-14)  The low TPO 
levels in MDS patients have been connected to an increase in megakaryocytes or TPO 
receptors on megakaryocytes,(13) but no studies have focused on the possibility of 
different TPO levels among MDS subtypes.  Patients with low-risk MDS could have 
high TPO levels and respond to IST like AA patients.  To test these hypotheses, plasma 
TPO was measured in patients with various types of MDS and correlated to IST 
response, patient prognosis and an increase in the percentage of GPI-AP- cells.   
 
Design and Methods 
Patient characteristics 
TPO plasma concentration was measured in 50 healthy volunteers (23 male, 27 female) 
18-82 years old (median age, 41 years) and 191 patients diagnosed with 
thrombocytopenia from 2005 to 2010 at Kanazawa University Hospital, hospitals 
participating in the Study Group of Intractable Hematopoietic Disorders in Japan, or 
other affiliated institutions.  There were 120 patients with MDS, including 37 with 
refractory cytopenia with unilineage dysplasia (RCUD), 40 with refractory cytopenia 
with multilineage dysplasia (RCMD), 22 with refractory anemia with excess of blasts 
(RAEB), and 21 with unclassified MDS (MDS-U), as well as 47 patients with AA and 
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24 with immune thrombocytopenia (ITP).  Characteristics of these participants are 
summarized in Table 1.  Patients dependent on platelet transfusions or with a liver 
dysfunction were excluded from the study.  AA and MDS were classified according to 
diagnostic criteria from the International Agranulocytosis and Aplastic Anemia Study 
Group and World Health Organization 2008, respectively.  Prognostic sores of 
MDS patients were calculated according to the International Prognostic 
Scoring System (IPSS).  AA severity was determined by criteria from Camitta et 
al.(15)  All patients with MDS were judged to have 30% or more marrow cellularity 
by pathologists.  MDS-U patients with abnormal karyotypes included 15 with del(13q), 
two with del(1;7), one with del(11q), one with t(4;21)(q11;q11), one with trisomy 8, and 
one with del(20q).  The patients with trisomy 8 and del(20q) were diagnosed with 
MDS-U by the presence of bicytopenia.  The ethics committee of Kanazawa 
University Graduate School of Medical Science approved the study protocol, and all 
patients provided their informed consent prior to sampling. 
 
Measurement of TPO levels 
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood was drawn from 
patients at diagnosis, and plasma was separated by centrifugation at 1000 g for 10 min 
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for storage at −20°C.  Plasma TPO was measured with a commercially available 
assay kit (QuantikineTM Human TPO Immunoassay, R&D Systems, Minneapolis, MN, 
USA) according to the manufacturer’s instructions.  Corrected TPO values were 




 blood cells 
EDTA-anticoagulated peripheral blood was drawn from each patient.  To detect 
GPI-AP- granulocytes, erythrocytes were lysed in buffer (8.26 g/L NH4Cl, 1.0 g/L 
KHCO3, and 0.037 g/L EDTA-4Na).  After a saline wash, 50 μL of leukocyte 
suspension was incubated with 4 μL of phycoerythrin (PE)-labeled anti-CD11b mAb 
(Becton Dickinson, Franklin Lakes, NJ, USA) and 6 μL of Alex Fluor 488-labeled 
inactive toxin aerolysin (FLAER; Pinewood Scientific Services, Victoria, BC, Canada).  
To detect GPI-AP- erythrocytes, fresh blood was diluted to 3% in phosphate buffered 
saline (PBS), and 50 μL was then incubated with 4 μL of PE-labeled anti-glycophorin A 
mAb (clone JC159; DAKO, Glostrup, Denmark), fluorescein-isothiocyanate (FITC)–
labeled anti-CD55 mAbs (clone IA10, mouse IgG2a; Pharmingen, San Diego, CA), and 
FITC-labeled anti-CD59 mAbs (clone p282, mouse IgG2a; Pharmingen).  At least 1 × 
105 CD11b+ granulocytes and glycophorin A+ red blood cells (RBCs) were analyzed 
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within each corresponding gate of a FACSCanto II® (Becton Dickinson) flow 
cytometer.(9)  A significant increase in the percentage of GPI-AP- cells was defined as 
greater than 0.003% aerolysin-CD11b+ granulocytes and/or greater than 0.005% 
glycophorin A+ RBCs as determined from the peripheral blood of 50 healthy individuals.  
Careful handling of samples with elaborate gating could lower the cut-off values to 
these levels without producing false positive results.(9, 16, 17)  
 
IST 
Horse anti-thymocyte globulin (ATG, Lymphoglobulin; Genzyme, Cambridge, MA, 
USA, 15 mg/kg/d) was administered for 5 days in combination with cyclosporine A 
(CsA; Novartis, Basel, Switzerland, 6 mg/kg/d).  CsA was also given at 5-6 mg/kg/d 
for at least 3 months as monotherapy.  Hematologic improvements, partial response, 
and complete response were defined by the International MDS Working Group 
Criteria.(18)      
 
Human androgen receptor assay (HUMARA) 
The androgen receptor gene was amplified from the genomic DNA of eight female 
patients, as previously described by Ishiyama et al. with some modifications.(19)  To 
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correct an inequality of amplification efficiency between the 2 alleles, we determined 
the ratios of both allele areas before (lower allele/higher allele: A/B) and after (lower 
allele/higher allele:A’/B’) HhaI digestion using a C value calculated by (A/B)/(A’/B’) 
as a marker of skewing in granulocytes (CG) and T lymphocytes (CL).  Skewing was 
judged evident when the absolute values of log (CG/CL) (S value) was more than 0.4.   
 
Statistical Analysis 
Plasma TPO concentrations were compared between subgroups with different clinical 
characteristics using the Mann-Whitney U test.  Receiver operating characteristic 
(ROC) curves were calculated from the TPO levels and corrected TPO values of AA 
patients (representing benign BM failure) and RAEB patients (representing preleukemic 
BM failure) to determine thresholds of plasma TPO levels and define patients with high 
TPO levels.  ROC curves were also calculated from the TPO levels of patients with 
early stage MDS who responded to IST and those who did not respond, and of patients 
who progressed to AML/death and those who did not progress.  The Kaplan-Meier 
method and the Cox proportional hazards model were performed to estimate 
time-to-event analysis.  Differences between patients with TPO levels ≥320 pg/mL 
(TPOhigh) and patients with TPO levels <320 pg/mL (TPOlow) were assessed by the 
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log-rank test.   The differences in the percentages of patients with low International 
Prognostic Scoring System (IPSS) scores and of patients requiring platelet transfusions 
between TPOhigh and TPOlow patients were assessed by Fisher’s exact probability test.  
All statistical analyses were performed using JMP version 5.0.1J software (SAS 
Institute, Cary, NC, USA). A P value < 0.05 was considered significant.   
  
Results 
TPO levels for patients with thrombocytopenia 
Plasma TPO levels ranged from 19.4 to 38.8 pg/mL (mean ± standard deviation, 54.5 ± 
21.1 pg/mL) in healthy individuals with platelet counts higher than 150 x 109/L.   
Similar to previous reports, TPO levels for patients with AA (1254.6 ± 551.1 pg/mL) 
were noticeably higher than for patients with ITP (63.5 ± 8.7 pg/mL) or RAEB (44.7 ± 
85.2 pg/mL) (Figure 1A).  Corrected TPO values were also higher in AA patients than 
RAEB patients (Figure 1B).  ROC curves set the threshold between benign and 
preleukemic BM failure at 320 pg/mL for TPO levels and 157 pg/mL/1010 L for 
corrected TPO values (Figure 2A).  All patients with TPO levels ≥320 pg/mL also had 
corrected TPO values >157 pg/mL/1010 L, except one with 155 pg/mL/1010 L, indicating 
that the difference between TPOhigh and TPOlow patients is not due to platelet count.  
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TPO levels were highly variable in patients with MDS subtypes other than RAEB, with 
the proportion of TPOhigh patients at 40.5% for RCUD, 32.5% for RCMD, and 77.3% 
for MDS-U.   
  
Prevalence of increased GPI-AP
-
cells, clonality, and IPSS scores for patients with 
MDS 
Small populations of GPI-AP- granulocytes and/or erythrocytes were detected in some 
MDS patients, at 29.7% for RCUD, 7.5% for RCMD, 62.9% for MDS-U, and 0% for 
RAEB.  Figure 3A displays the percentage of GPI-AP- granulocytes in 55 TPOhigh (25 
with RCUD, 14 with RCMD, and 16 with MDS-U) and 65 TPOlow (12 with RCUD, 26 
with RCMD, 5 with MDS-U, and 22 with RAEB) patients.  The prevalence of 
increased GPI-AP- granulocytes and/or erythrocytes in each group was 45.8% and 0% 
(P = 0.003, Figure 3B).  Eight female patients (four with RCMD and four with 
MDS-U) underwent the HUMARA.  All four TPOlow patients showed S values more 
than 0.4 (1.23, 1.39, 1.14, and 0.71) compatible with the presence of clonal 
hematopoiesis while none of the four TPOhigh patients showed such high S values (0.06, 
0.16, 0.08, and 0.09, P = 0.002, Supplementary Figure 2).  When correlation of TPO 
levels and IPSS scores was examined for each MDS patient, none of the TPOhigh 
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patients had an IPSS score above 1.5 (Figure 3C).  In fact, the percentages of 0, 0.5, or 
1.0 scores in TPOhigh and TPOlow patient groups were 100.0% and 65.5%, respectively 
(P < 0.001).  
  
Response of patients with MDS to IST 
Forty-five TPOhigh MDS patients were treated with IST.  Sixteen patients (seven with 
RCUD and nine with MDS-U) were treated with a combination of ATG and CsA, while 
29 patients (nine with RCUD, 10 with RCMD, and 10 with MDS-U) were treated with 
CsA alone.  Response rates to ATG+CsA and CsA were 81.2% and 85.3%, respectively.  
In contrast, seven TPOlow patients received CsA monotherapy which produced only one 
case of improved anemia (from 5.4 g/dL to 8.1 g/dL).  The cumulative rate of response 
to IST in TPOhigh patients was significantly higher than that in TPOlow patients (P=0.002, 
Supplementary Figure 1A), while there was no significant difference either between 
patients with or without increased GPI-AP- granulocytes (P=0.38, Supplementary 
Figure 1B) or between TPOhigh patients with or without increased GPI-AP- granulocytes 
(P=0.28, Supplementary Figure 1C).  ROC analysis revealed the threshold TPO level 
affecting the response to IST to be 286.7 pg/mL, with a sensitivity of 0.580 and a 
specificity of 0.850 (Figure 1B). 
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After 6 to 17 months of IST, TPO levels were measured again in four patients who 
achieved a platelet recovery above 100 x 109/L.  The corrected TPO levels before and 
after IST were 718.7/14.2 pg/mL/1010 L, 266.8/10.8 pg/mL/1010 L, 330.6/8.75 
pg/mL/1010 L, and 170.6 /8.8 pg/mL/1010 L.   
 
Correlation of high TPO levels with the prognosis of patients with MDS 
The 5-year overall survival rates for RCUD, RCMD, MDS-U, and RAEB patients were 
53.6%, 50.8%, 53.1%, and 37.4%, respectively (Figure 4A).  The 5-year 
progression-free survival (PFS) rates for RCUD, RCMD, and MDS-U patients were 
60.9%, 60.6%, and 71.4%, respectively (Figure 4B).  The 5-year PFS rates, defined as 
whichever came first among time from the first day of diagnosis until progression to 
AML or disease related death, was significantly higher for TPOhigh patients than TPOlow 
patients with RCUD (94.1% versus 60.6%, P=0.03) or RCMD (100.0% versus 44.4%, 
P=0.006), while there was no significant difference between the two groups in patients 
with MDS-U (82.3% versus 80.0%, P=0.22, Figure 4C).  An ROC analysis revealed 
the threshold TPO level affecting progression to AML to be 244.2 pg/mL with a 
sensitivity of 0.927 and a specificity of 0.636 (Figure 1C).  A multivariate analysis on 
patients with RCUD, RCMD and MDS-U revealed TPOlow and patient gender to be 
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significant factors associated with progression to AML (Table 2).  In contrast to 
previous analyses (20), red blood cell transfusion requirements were not identified as a 
significant prognostic factor in this study cohort.  This may reflect the fact that we 
selected patients with thrombocytopenia.  There was no significant difference in the 
percentages of patients requiring platelet transfusions among TPOhigh (8/52, 4.3%) and 
TPOlow (2/46, 15.3%, P=0.09) patients.  TPO levels were serially recorded for one 
patient as AA evolved into MDS-RAEB 20 months after IST.  The TPO concentration 
was 1960 pg/mL at the onset of AA and 151 pg/mL when thrombocytopenia recurred 
with the emergence of atypical blasts in peripheral blood (Supplementary Figure 3).   
 
Discussion 
Consistent with previous reports, the present study revealed an increase in the TPO 
levels of patients with AA, a decrease in those with ITP, and relatively low TPO levels 
in patients with MDS.(13, 14)  While patients with RAEB had consistently low TPO 
levels, patients with low-risk MDS (RCUD, RCMD, and MDS-U) produced highly 
variable results.  Feng et al. recently demonstrated similar variability among patients 
with hypoplastic MDS and reported the usefulness of TPO in distinguishing hypoplastic 
MDS from AA;(21) however, the significance of high TPO levels in a subset of patients 
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with low-risk MDS was not focused on by the authors.  Our study is the first to 
demonstrate that a high concentration of TPO is associated with benign BM failure in 
patients with MDS as seen by the higher prevalence of increased GPI-AP- cells, lower 
incidence of clonal hematopoiesis, lower IPSS score, and better PFS in TPOhigh patients 
compared to TPOlow patients.  The negative prognostic impact of TPO levels <320 
pg/mL was confirmed by a multivariate analysis, which also identified patient gender to 
be a poor prognostic factor as demonstrated by previous studies. (22, 23) 
Plasma TPO levels are negatively regulated by platelets and megakaryocytes 
through their binding of TPO.(24, 25)  Some studies show an inverse correlation 
between TPO levels and BM megakaryocyte count (26, 27), but the TPO levels of 
patients with RAEB were consistently low in our study despite the low megakaryocyte 
content (data not shown).  Low TPO levels in MDS patients with a poor prognosis may 
be explained by an increased turnover of platelets produced by abnormal 
megakaryocytes (28).  We previously demonstrated that the aberrant increase in the 
proportion of immature platelets is frequently seen in MDS patients with chromosomal 
abnormalities associated with poor prognosis (28).  Increased production and 
destruction of platelets may accelerate TPO consumption in patients with RAEB, 
leading to a decrease in plasma TPO levels.  Although one report demonstrated 
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increased TPO receptors on the megakaryocytes of MDS patients using flow cytometry, 
(14) we were unable to reproduce their results (data not shown).   
Small populations of GPI-AP- cells have been detected in a subset of patients 
with refractory anemia as defined by French-American-British classification and are 
associated with a favorable response to IST and good future prognosis.(2)  Patients 
with increased GPI-AP- cells (PNH+ patients) are characterized by predominant 
thrombocytopenia and no increase in BM megakaryocytes,(6, 9) which agrees with our 
findings of high TPO levels in all PNH+ patients with MDS and no PNH+ patients with 
low TPO levels.  These results show no need to examine peripheral blood for GPI-AP- 
cells in patients with BM failure if their TPO levels are less than 320 pg/mL.   
The response rate to ATG+CsA therapy or CsA monotherapy for TPOhigh MDS 
patients was as high as or higher than the response for AA patients.(29)  When we 
previously assessed the efficacy of CsA therapy for patients with thrombocytopenia and 
decreased BM megakaryocytes, more than 70% improved regardless of the presence or 
absence of GPI-AP- cells (unpublished observation).  High TPO levels may have a 
stronger association with the immune pathophysiology of BM failure in a subset of 
MDS than the presence of increased GPI-AP- cells.  However, the impact of the 
increased percentage of GPI-AP- granulocytes on PFS could not be analyzed by our 
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multivariate analysis because all patients with increased GPI-AP- granulocytes were 
sorted into the TPOhigh group.  When we conducted another multivariate analysis using 
increased GPI-AP- granulocytes, rather than TPO levels, as an independent factor, the 
hazard ratio of the increased GPI-AP- granulocytes was 0.64, with a P-value of 0.69.  
Thus, the impact of increased GPI-AP- granulocytes on PFS appears to be much smaller 
than high TPO levels.   
Previous reports documented the important role of DRB1*1501 as a predictor of 
response to IST in patients with MDS (8). This factor may also have affected PFS in our 
patient cohort.  Unfortunately, since only a limited number of patients underwent HLA 
typing, its impact on PFS could not be determined in this study. However, we previously 
examined various factors, including GPI-AP- cells and DRB1*1501, for their 
association with good response to IST in 140 patients with AA using multivariate 
analysis and found that only the presence of increased GPI-AP- cells significantly 
predicts favorable response to IST(30, 31).  Thus, it is unlikely that DRB1*1501 
affects PFS of patients with MDS more strongly than increased GPI-AP- cells or high 
TPO levels.  Cytogenetic abnormality was not identified as a poor risk factor by the 
multivariate analysis.  This is probably because 15 of 21 patients with cytogenetic 
abnormalities had del(13q), which represents benign BM failure with immune 




Although the exact mechanism for decreased TPO in MDS patients with a poor 
prognosis remains unclear, measurement of its concentration could play a significant 
role in managing MDS with thrombocytopenia.  A patient with TPO levels ≥320 
pg/mL is considered to have a good prognosis with a small likelihood of developing 
AML, and IST can be considered rather than radical treatments such as chemotherapy 
and stem cell transplantation.  Recent National Comprehensive Cancer Network 
guidelines recommend hypomethylating agents as a treatment for MDS patients with 
thrombocytopenia,(33) but this option may be hazardous to TPOhigh patients because 
their BM failure is not based on abnormal stem cells with preleukemic features.  
Measurement of TPO levels is therefore recommended for patients with low-risk MDS 
and thrombocytopenia so that the most appropriate therapy can be chosen.  The exact 
role of TPO levels in the management of MDS will need to be evaluated with a 
prospective study.   
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 Table 1. Characteristics of study participants with thrombocytopenia and healthy 
volunteers.  






Platelet count (×109/L), 
(median ± SE) 
MDS 120 60/49 70 (19-91) 54.0 ± 2.7 
 RCUD 37 17/20 65 (46-85) 53.7 ± 4.3 
 RCMD 40 23/17 69 (33-91) 43.5 ± 8.2 
 RAEB 22 16/6 74 (43-85) 49.1 ± 2.7 
 MDS-U 21 10/11 72 (19-76) 62.2 ± 2.1 
AA 47 25/22 58 (12-93) 24.9 ± 7.3 
 Severe 23 12/11 56(28-93) 11.6 ± 6.9 
 Moderate 24 13/11 58(12-83) 43.9 ± 5.4 
ITP 24 14/10 62(35-82) 23.5± 7.9 
Healthy volunteers 50 23/27 41 (18-59) 304.3 ± 8.6 
MDS, myelodysplastic syndrome; RCUD, refractory cytopenia with unilineage 
dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory 
anemia with excess of blasts; MDS-U, unclassified myelodysplastic syndromes; AA, 
aplastic anemia; ITP, immune thrombocytopenia; HV, healthy volunteers. 
 
 
Table 2. Multivariate analysis of factors negatively affecting progression-free survival 
of patients with myelodysplastic syndrome 
 hazard ratio P-value 
TPO (pg/mL) 
<320 vs ≥320 
0.05 0.009 
Age (years old) 
  <60 vs ≥60 
1.87 0.262 
Sex 
female vs male 
0.12 0.009 
IPSS 
0 vs 0.5 and 1.0 
0.34 0.158 
Transfusion 
yes vs no 
1.21 0.752 
Abnormal karyotype 
yes vs no 
0.93 0.916 
 




Figure 1. Plasma thrombopoietin levels in patients with thrombocytopenia and healthy 
volunteers. (A) Plasma thrombopoietin (TPO) levels for each patient group.  (B) 
Corrected TPO values for each patient group.  The horizontal line in each figure 
represents the cut-off value that potentially separates benign and preleukemic bone 
marrow failure.  RCUD, refractory cytopenia with unilineage dysplasia; RCMD, 
refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess 
of blasts; MDS-U, unclassified myelodysplastic syndromes; AA, aplastic anemia; ITP, 
immune thrombocytopenia; HV, healthy volunteers.   
 
Figure 2. Receiver operating characteristic (ROC) curves to determine thresholds of 
plasma TPO levels discriminating benign (aplastic anemia)/preleukemic BM failure 
(RAEB, A), response/no response to immunosuppressive therapy (IST, B), and 
progression/no progression to AML/death (C). 
 
Figure 3. Relationship between thrombopoietin levels and other prognostic markers for 
patients with myelodysplastic syndrome.  (A) Percentage of GPI-AP- granulocytes in 
TPOhigh (n = 55) and TPOlow (n = 65) patients.  The horizontal line represents the 
cut-off value that separates significant and non-significant increases in GPI-AP- 
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granulocyte percentage.  (B) The prevalence of increased GPI-AP- granulocytes and/or 
erythrocytes in TPOhigh (n = 55) and TPOlow (n = 65) patients.  (C) TPO levels for 
MDS patients classified by IPSS score.  GPI-AP- cells, 
glycosylphosphatidylinositol-anchored protein-deficient cells; TPOhigh, thrombopoietin 
levels ≥320 pg/mL; TPOlow, thrombopoietin levels <320 pg/mL; RCMD, refractory 
cytopenia with multilineage dysplasia; MDS-U, unclassified MDS; AA, aplastic 
anemia; IPSS, International Prognostic Scoring System. 
 
Figure 4. Influence of thrombopoietin levels at diagnosis on survival rates of patients 
with myelodysplastic syndrome.  (A) Overall survival and (B) PFS of patients with 
myelodysplastic syndrome (MDS; 37 with RCUD, 40 with RCMD, 21 with MDS-U, 
and 20 with RAEB); (C) PFS of TPOhigh and TPOlow patients by MDS subtypes.  The 
numbers of TPOhigh/TPOlow patients for each subtype were 17/22 for RCUD, 13/27 for 
RCMD, and 16/5 for MDS-U.  RCUD, refractory cytopenia with unilineage dysplasia; 
RCMD, refractory cytopenia with multilineage dysplasia; MDS-U, unclassified MDS; 
AA, aplastic anemia; PFS, Progression free survival; TPOhigh, thrombopoietin levels 
≥320 pg/mL; TPOlow, thrombopoietin levels <320 pg/mL. 
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Supplementary Figure 1. Cumulative rates of response to IST in different subsets of patients defined 
by TPO levels and the increase in percentages of GPI-AP- granulocytes. A, TPOhigh and TPOlow 
patients; B, patients with or without increased GPI-AP- granulocytes; C, TPOhigh patients with or 
without increased GPI-AP- granulocytes. 
 
Supplementary Figure 2. Skewing of the inactivation pattern for androgen receptor genes from the 
granulocytes of patients with myelodysplastic syndromes (MDS).  Representative human androgen 
receptor assay results for two TPOhigh patients (top; left, RCMD and right, MDS-U) and two TPOlow 
patients (bottom; left, RCMD and right, MDS-U) are shown.  The S value represents the absolute 
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Supplementary Figure 3. Clinical course of a patient with aplastic anemia that evolved into refractory 
anemia with excess of blasts as thrombopoietin levels decreased.  Bone marrow examination 
revealed the presence of 8.8% myeloblasts and hypogranular neutrophils, as well as a 
pseudo-Pelger-Huet nucleus, with the recurrence of pancytopenia in October 2010.  Plt, platelet 
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